The KLC4 Knockout HAP1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population disrupting the KLC4 gene in the near-haploid HAP1 cell line. This product offers a heterogeneous pool of edited alleles, each carrying targeted gene disruptions that abrogate KLC4 function. The polyclonal nature ensures a robust loss-of-function model suitable for high-throughput screening and pathway analysis, without the need for single-cell cloning. Researchers can leverage this tool to investigate kinesin-1-dependent intracellular transport and its roles in disease.
HAP1 cells are derived from the KBM-7 chronic myeloid leukemia (CML) cell line, isolated from a male patient. Characterized by a near-haploid karyotype, HAP1 contains a single copy of most chromosomes, simplifying CRISPR/Cas9-mediated knockout as only one allele requires targeting. As a hematopoietic tumor cell line, HAP1 retains properties relevant to leukemia biology while providing a genetically tractable background for functional genomics. This minimal genetic redundancy facilitates unambiguous phenotypic interpretation following gene disruption.
KLC4 encodes a light chain subunit of the kinesin-1 motor complex, which drives microtubule-based transport. KLC4 forms heterotetramers with heavy chains such as KIF5B and directly binds cargo adaptors including TRAK2/Milton and JIP1 to link motors to organelles like mitochondria and vesicles carrying amyloid precursor protein (APP). KLC4 activity is modulated by upstream kinases GSK3?? and JNK via phosphorylation, regulating cargo attachment and transport processivity. Disruption of KLC4 therefore uncouples kinesin-1 from its cargoes, impairing axonal transport, mitochondrial distribution, and cell migration. Key pathway components interacting with or regulated by KLC4 include microtubules, KIF5B, TRAK2, and JIP1.
In the HAP1 background, KLC4 knockout provides a clean genetic model to dissect kinesin-mediated transport without interference from a second functional allele. The leukemic origin of HAP1 positions this model to study the role of KLC4 in hematopoietic cell migration and cancer metastasis, as KLC4 has been implicated in promoting cell motility. Furthermore, given the links of KLC4 to neurodegenerative diseases such as Alzheimer disease and spastic paraplegia, this cellular model can be used to explore basic mechanisms of mitochondrial trafficking and axonal transport that are critical in neuronal health. The loss of KLC4 in HAP1 cells mimics trafficking defects observed in these pathologies.
This polyclonal knockout cell population supports diverse research applications. Functional genomic screens can identify synthetic lethal interactions or modifiers of kinesin-1-dependent pathways. Drug target validation studies can assess whether KLC4 disruption alters sensitivity to therapeutic agents using drug sensitivity testing. Cell migration assays quantify changes in motility, while immunofluorescence and mitochondrial distribution analysis visualize cargo mislocalization. Western blotting confirms KLC4 protein ablation. Collectively, this model enables investigation of kinesin-1 biology in cancer and neurodegeneration. For further information, please contact Ascent Research.
